GLIPR1L2 Antibody
| Code | Size | Price |
|---|
| PSI-7639-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-7639-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Western Blot (WB)
Documents
Further Information
Additional Names:
GLIPR1L2 Antibody: GLIPR1-like protein 2
Application Note:
GLIPR1L2 antibody can be used for detection of GLIPR1L2 by Western blot at 1 - 2 μg/ml. Antibody can also be used for Immunohistochemistry starting at 5 μg/mL. For immunofluorescence start at 20 μg/mL.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Background:
The GLIPR1-like 2 protein (GLIPR1L2) gene is part of a p53 target gene cluster that includes the related proteins GLIPR1 and GLIPR1L2 (2). GLIPR1L2 is similar to both the pathogenesis-related protein (PR) superfamily and the cysteine-rich secretory protein (CRISP) family (1). GLIPR1 is a tumor suppressor whose expression is regulated by p53 (3). Deletions of the GLIPR1/GLIPR1L1/GLIPR1L2 gene cluster have been observed in some multiple myeloma samples, suggesting that these proteins may also be involved in the pathogenesis of multiple myeloma (4).
Background References:
- Ren C, Ren CH, Li L, et al. Identification and characterization of RTVP1/GLIPR1-like genes, a novel p53 target gene cluster. Genomics 2006; 88:163-72.
- Murphy EV, Zhang Y, Zhu W, et al. The human glioma pathogenesis-related protein is structurally related to pathogenesis-related proteins and its gene is expressed specifically in brain tumors. Gene 1995; 159:131-5.
- Ren C, Li L, Yang G, et al. RTVP-1, a tumor suppressor inactivated by methylation in prostate cancer. Cancer Res. 2004; 64:969-76.
- Tam M, Lin P, Hu P, et al. Examining hedgehog pathway genes GLI3, SHH, and PTCH1 and the p53 target GLIPR1/GLIPR1L1/GLIPR1L2 gene cluster using fluorescence in situ hibridization uncovers GLIPR1/GLIPR1L1/GLIPR1L2 deletion in 9% of patients with multiple myeloma. J. Assoc. Genet. Technol. 2010; 36:111-4.
Buffer:
GLIPR1L2 antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
GLIPR1L2 antibody was raised against an 15 amino acid peptide near the center of human GLIPR1L2.
The immunogen is located within amino acids 120 - 170 of GLIPR1L2.
The immunogen is located within amino acids 120 - 170 of GLIPR1L2.
NCBI Gene ID #:
144321
NCBI Official Name:
GLI pathogenesis-related 1 like 2
NCBI Official Symbol:
GLIPR1L2
NCBI Organism:
homo sapiens
Physical State:
Liquid
PREDICTED MOLECULAR WEIGHT:
Predicted: 28, 31, 38 kDa
Observed: 28 kDa
Observed: 28 kDa
Protein Accession #:
NP_001257325
Protein GI Number:
394025727
Purification:
GLIPR1L2 antibody is affinity chromatography purified via peptide column.
Research Area:
Cancer,Cell Cycle
SPECIFICITY:
GLIPR1L2 antibody is human specific. At least two isoforms of GLIPR1L2 are known to exist; this antibody will detect both isoforms. This antibody is predicted to not cross-react with other GLIPR or GLIPR-like proteins.
Swissprot #:
Q4G1C9
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | GLIPR1L2 Peptide | PSI-7639P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|